TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2383925
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 50 mU of biosynthetic human growth hormone (b‐hGH)
Study: 2383925
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of somatostatin (1‐14)
Study: 2383925
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of exogenous hormone (3 mU/kg/h) for 15, 30, 60 and 180 min
Study: 796740
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron 1-2 g every 4 months
Study: 796740
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron plus testosterone
Study: 796740
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron and androgens
Study: 23641902
Drug: Campath (alemtuzumab)-based
Normalized name: alemtuzumab Injection [Campath]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath (alemtuzumab)-based induction therapy
Study: 23641902
Drug: Sirolimus-based maintenance
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-based maintenance therapy
Study: 23641902
Drug: Basiliximab-based therapy
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab-based therapy
Study: 19345060
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention including standard treatment, supervised exercise program (4-6 weeks, 1 hour/day, 5 days/week), progressive relaxation, and psychoeducation.
Study: 19345060
Drug: Standard treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment, care, and physiotherapy (control group).
Study: 11305517
Drug: New fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New fecal calprotectin method with a cut-off limit of 50 microg/g
Study: 11305517
Drug: Original fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original fecal calprotectin method with a cut-off limit of 10 mg/l
Study: 11305517
Drug: New fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New fecal calprotectin method with a cut-off limit of 150 microg/g
Study: 2973777
Drug: Enoximone (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (low doses ≤ 1 mg/kg) in group A (n = 11)
Study: 2973777
Drug: Enoximone (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (high doses > 1 mg/kg) in group B (n = 12)
Study: 24610603
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel (10 ml)
Study: 24610603
Drug: Liquid paraffin
Normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid paraffin (10 ml)
Study: 21778294
Drug: Morphine (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.07 mg/kg)
Study: 17020434
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs
Study: 11553427
Drug: Adjunct questions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct questions (AQ)
Study: 9863075
Drug: TCM‐WM therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM‐WM therapy (DMSA and Gandou decoction for 1 month)
Study: 9863075
Drug: WM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WM therapy (DMSA only)
Study: 30506558
Drug: Carbetocin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin 20 μg
Study: 31599627
Drug: Duluth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duluth treatment program
Study: 31247165
Drug: Psychomotor Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychomotor Therapy (PMT) in combination with Active Exercise (AE) for 12 weeks
Study: 28279704
Drug: Pharmaceutical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical placebo
Study: 19371313
Drug: sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sildenafil 100 mg + sublingual GTN 400 microg
Study: 19371313
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + sublingual GTN 400 microg
Study: 16791814
Drug: External radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiation therapy targeted on the neck and upper mediastinum
Study: 16791814
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of newly formed lymph node metastases
Study: 24016557
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment results
Study: 10695915
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 1)
Study: 10695915
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (6 microg kg(‐1) min(‐1)) during 6 h (group 2)
Study: 10695915
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (group 3)
Study: 10695915
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (group 4)
Study: 9180060
Drug: Conventional pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional pharmaceutical therapy (primarily amiodarone)
Study: 29514234
Drug: Enhanced prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced prophylaxis (cotrimoxazole plus 12 weeks of isoniazid + fluconazole, single-dose albendazole, and 5 days of azithromycin)
Study: 23959817
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (intratympanic methylprednisolone + oral steroid)
Study: 23959817
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid alone
Study: 19180895
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% methylene blue (MB) hydrogel with photodynamic therapy (PDT) using 565 mW LED 670 nm light
Study: 19180895
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% methylene blue (MB) hydrogel
Study: 19180895
Drug: Histopathological examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histopathological examination post-treatment
Study: 17923598
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (mean dose 1.3 ± 0.4 mg/kg)
Study: 15318852
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ASA 12 hours before apheresis (Group A)
Study: 15318852
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication before donation (Group B)
Study: 11831838
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg once daily
Study: 9848591
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac supplemented by oral oxycodone
Study: 9848591
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine via patient‐controlled analgesia (PCA) device
Study: 10890259
Drug: Cefdinir 300
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 300 mg BID
Study: 9589816
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg QID
Study: 1884609
Drug: Polyclonal immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal immunoglobulin preparation (n = 27)
Study: 31699029
Drug: Intravenous loop
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous loop diuretics (LDs)
Study: 23895672
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (angioplasty or stenting)
Study: 22440436
Drug: Interactive computer‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive computer‐based tool (CatInfo) containing a detailed audiovisual presentation about cataract and its treatment
Study: 18769351
Drug: darunavir/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/r 800/100 mg once daily
Study: 18769351
Drug: darunavir/r 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/r 600/100 mg twice daily
Study: 12388173
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate weekly (group 1)
Study: 9659025
Drug: mivacurium 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.04 mg.kg‐1
Study: 9659025
Drug: mivacurium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.08 mg.kg‐1
Study: 8521310
Drug: propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 2.5 mg.kg‐1
Study: 8070508
Drug: Oral Cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cyclosporin (CsA) solution (mean daily dose: 23.3 mg.kg‐1) in CF subjects
Study: 8070508
Drug: Oral Cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cyclosporin (CsA) solution in non-CF subjects (mean daily dose: 4.8 mg.kg‐1)
Study: 2904313
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (0.25 to 8 micrograms min‐1 kg‐1)
Study: 2904313
Drug: Metoclopramide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide infusion
Study: 17543392
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment
Study: 14508327
Drug: Acetazolamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (5 mg/kg)
Study: 9037361
Drug: Filgrastim 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 1.0 microgram/kg s.c. daily for 3‐7 days followed by CEOP with filgrastim support 10 micrograms/kg s.c. daily, day 2‐14
Study: 9037361
Drug: CEOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP chemotherapy (C 500 mg/m2, E 37.5 mg/m2, O 2 mg, P 75 mg/m2)
Study: 9037361
Drug: CEOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP chemotherapy (C 750 mg/m2, E 50 mg/m2, O 2 mg, P 75 mg/m2)
Study: 1577056
Drug: Theophylline 5
Normalized name: theophylline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 5 mg.kg-1 per day with omeprazole 20 mg per day
Study: 1577056
Drug: Theophylline 5
Normalized name: theophylline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 5 mg.kg-1 per day with placebo
Study: 3000412
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus ACNU (100 mg/m2 on day 1 and 42)
Study: 3000412
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus ACNU and tegafur (400 mg/m2, daily for 8 weeks)
Study: 29193478
Drug: Carvacrol capsule
DrugBank: Carvacrol (DB16404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvacrol capsule (1.2 mg/kg/day) for 2 months
Study: 20451896
Drug: Ahmed valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed valve implant (model FP7; 184 mm² surface area)
Study: 20451896
Drug: Molteno single-plate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molteno single-plate implant (134 mm² surface area)
Study: 18630765
Drug: levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: levobupivacaine 0.25% 10 mL epidurally
Study: 18630765
Drug: piritramide 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: piritramide 0.08 mg kg(‐1) i.v.
Study: 9045347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carboplatin and paclitaxel
Study: 7590485
Drug: Intraperitoneal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal therapy
Study: 15839958
Drug: Maintenance/consolidation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance/consolidation therapy
Study: 15839958
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of a third non-cross-resistant drug to carboplatin and paclitaxel
Study: 11886010
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) treatment
Study: 9987087
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg FU plus a sham infusion
Study: 9987087
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg FU plus 200 ml of a 20% solution of HA
Study: 9987087
Drug: Sham infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham infusion plus 200 ml of a 20% solution of HA
Study: 7027893
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 12.5 mg (group A) b.i.d for 12 weeks
Study: 7027893
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of metoprolol 100 mg and hydrochlorothiazide 25 mg (group B) b.i.d for 12 weeks
Study: 7027893
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination of hydrochlorothiazide with metoprolol
Study: 30381901
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (approximately 25 g of protein from 125 g per week of sardine, advised to restrict carbohydrate intake)
Study: 27853891
Drug: Ginsenoside Rb1
Normalized name: Ginsenoside Rb1
DrugBank: Ginsenoside Rb1 (DB06749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside Rb1 (500 mg daily oral administration, n = 103)
Study: 24422876
Drug: Manual therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy-based physiotherapy intervention (C)
Study: 14702492
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (aimed at providing 1800 mg of Ca/day)
Study: 11720117
Drug: Nottingham Extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nottingham Extended Activities of Daily Living Scale (NEADL)
Study: 9204354
Drug: Iopromide (Ultravist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (Ultravist 300 mg I/ml)
Study: 3610514
Drug: 0.1% benzydamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% benzydamine solution
Study: 3610514
Drug: povidone-iodine vaginal
Normalized name: povidone-iodine Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: povidone-iodine vaginal suppositories
Study: 3610514
Drug: 0.2% aluminium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% aluminium acetate solution
Study: 29042177
Drug: Any change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any change in antibiotic exposure
Study: 27827949
Drug: Hypoxia +
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxia + carbohydrate supplementation (6% carbohydrate solution, maltodextrin)
Study: 30857448
Drug: Oral squamous
Normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral squamous cell carcinoma (OSCC) patients
Study: 18023439
Drug: Triptorelin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (0.2 mg SC) in addition to hCG (5,000 U) 34 hours before oocyte aspiration
Study: 1433581
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with prophylactic antibacterials
Study: 4080137
Drug: High anxiety
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High anxiety treatment group
Study: 4080137
Drug: Low anxiety
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anxiety treatment group
Study: 29435364
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg and 75 mg
Study: 20672296
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID) for up to nine courses (28 days on/28 days off)
Study: 20672296
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aztreonam for inhalation solution (AZLI) administered two (BID) or three times daily (TID)
Study: 8032546
Drug: 0.9 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously once weekly (4 doses, stratum I)
Study: 8032546
Drug: 0.9 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously three times a week every other day (9 doses, stratum II)
Study: 8032546
Drug: 0.9 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 MIU/m2 IL-2 administered subcutaneously five times a week every other week (10 doses, stratum III)
Study: 1091171
Drug: Oral colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colistin sulfate (non-absorbable broad-spectrum antimicrobial)
Study: 23356250
Drug: Lime juice
Normalized name: lime juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lime juice treatment
Study: 2189276
Drug: Ankerplast Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankerplast Spray
Study: 2189276
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Ankerplast Spray)
Study: 30742122
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy alone
Study: 24078483
Drug: Active group
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active group received LLLT using a 'TOPHAT655' unit with 21 lasers (5 mW, 655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments).
Study: 24078483
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received a unit with incandescent red lights, treated at home every other day for 16 weeks (60 treatments).
Study: 19664320
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy (CBGT)
Study: 15305399
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of epirubicin (90 mg/m2) and paclitaxel (200 mg/m2) for 8 cycles
Study: 15305399
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of epirubicin (120 mg/m2 for 4 cycles) followed by paclitaxel (250 mg/m2 over 3 hours for 4 cycles)
Study: 11453871
Drug: Vitamin E-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E-modified membrane (E) with Vitamin C infusion (C)
Study: 11453871
Drug: Nonmodified cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmodified cellulose membrane (O) with Vitamin C infusion (C)
Study: 2454128
Drug: 6% dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% dextran added to lignocaine solution containing adrenaline
Study: 2454128
Drug: Lignocaine solution
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine solution containing adrenaline without dextran
Study: 25212278
Drug: IMN (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMN (0.6 L/d)
Study: 25486372
Drug: Cognitive-Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavior Therapy (CBT)
Study: 19367116
Drug: Probiotics (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (various strains such as Bifidobacterium, Lactobacillus, and Lactococcus) administered during the perinatal period
Study: 15110921
Drug: Hydrocortisone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (5 or 10 mg, p.o.)
Study: 15110921
Drug: CRH stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH stimulation (1 g/kg i.v.)
Study: 8463575
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg on days 1 and 2)
Study: 2939218
Drug: Ketanserin (K),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (K), 40 mg/day
Study: 2939218
Drug: Metoprolol (M),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (M), 200 mg/day
Study: 20002596
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/day (re-randomized from placebo or milnacipran 100 mg/day)
Study: 20002596
Drug: Milnacipran 200
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 200 mg/day (for patients re-randomized from placebo)
Study: 18754195
Drug: Ibuprofen-releasing foam
Normalized name: ibuprofen Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-releasing foam dressing (Biatain Ibu, ColoplastA/S)
Study: 15286005
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg or 10 mg/kg every four or eight weeks)
Study: 12799626
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha QW (0.5, 1.0, 2.25, or 4.5 micro g kg(‐1) week(‐1) for 12 weeks)
Study: 12799626
Drug: Darbepoetin alpha
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alpha Q3W (6.75 micro g kg(‐1) for 12 weeks)